Adaptimmune Therapeutics plc American Depositary Shares

Adaptimmune Therapeutics plc American Depositary Shares

ADAP Stock Report Card





Score: 10/100


ADAP returned -24.31% in the last 12 months. Based on the other stocks in its sector with an average return of -5.72%, its performance is below average giving it a grade of 10 of 100.


Score: 75/100


8 analysts offer 12-month price forecasts for ADAP. Together, they have an average target of 3, the most optimistic forecast put ADAP at 3 within 12-months and the most pessimistic has ADAP at 3.


Score: 67/100


ADAP had a bullish sentiment score of 67.20% across Twitter and StockTwits over the last 12 months. It had an average of 15.74 posts, 110.25 comments, and 258.92 likes per day.


Score: 11/100


ADAP receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.


Score: 10/100


ADAP has missed earnings 8 times in the last 20 quarters.


Score: 10/100


Out of the last 20 quarters, ADAP has had 2 profitable quarters and has increased their profits year over year on 1 of them.


Score: 51/100


ADAP has had a higher than average amount of volatility over the last 12 months giving it a grade of 50 of 100.

Adaptimmune Therapeutics plc American Depositary Shares Summary

Nasdaq / ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
pluto logo
Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.